Abstract
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy that induces microvesicular injury and occlusion and often results in acute renal failure. Atypical HUS is life-threatening and often progresses to end-stage renal disease (ESRD). However, distinguishing between typical and atypical HUS can be challenging due to comorbid conditions and/or laboratory delays. We present a severe case of typical HUS involving a series of complications requiring multidisciplinary care, successfully treated with eculizumab therapy.